Recombinant KGF treatment has been studied for use in ulcerative colitis; in a clinical phase II study, recombinant KGF failed to induce remission in ulcerative colitis patients, but the maximal therapeutic dose used may have been too low [66]. This evidence concerns the gene FGF7 and ulcerative colitis.